Loading news...
Sold 62,013 shares of Kymera Therapeutics; estimated transaction value $4.19 million (based on mean unadjusted close for the quarter). The quarter-end position value increased by $2.41 million, reflecting both share sales and price movement.
Bamco Inc. NY purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ: KYMR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 7,000 shares of the company's stock, valued at approximately $396,000. A number of other institutional investors and hedge funds
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that data from its KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented in a late-breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO. Kymera will also host a booth (#3551) in the congress exhibit hall.
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into the clinic.
Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million in FY25, reflecting aggressive advancement of KT-621 and KT-579 into mid-stage trials, prioritizing long-term value over near-term profitability. KT-621's Phase 2b trials in atopic dermatitis and eosinophilic asthma are key 2027 catalysts; KT-579's Phase 1 data in autoimmune diseases is expected in 2H26.
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares in
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) has earned a consensus recommendation of "Buy" from the twenty-two ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, nineteen have issued a buy rating and two have given a strong buy rating to
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.88 per share a year ago.
Baker Bros. Advisors added 2,005,813 shares of Kymera Therapeutics; the estimated transaction value was $135.45 million.
WATERTOWN, Mass. , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026.
Rock Springs Capital Management bought 46,497 shares of Kymera Therapeutics in the fourth quarter, with an estimated trade value of $3.14 million (based on quarterly average pricing). Meanwhile, the quarter-end position value increased by $13.17 million, reflecting share additions and price movement.
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) has been given a consensus recommendation of "Buy" by the twenty-two brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nineteen have issued a buy recommendation and two have assigned a strong buy recommendation to the
Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.
SG Americas Securities LLC lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 61.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,432 shares of the company's stock after selling 13,633 shares during the period.
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026 Well-capitalized with $1.6 billion 1 in cash and runway into 2029 Kymera to present its 2026 objectives at the J.P. Morgan 44 th Annual Healthcare Conference today at 9:00 a.m.
Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).